Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00975143 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
A Phase 3 study, sponsored by Cipher Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 925
- Enrollment target
NCT00975143 is a Phase 3 study that has completed, run by Cipher Pharmaceuticals. The registered enrollment target is 925 participants.
The verdict
NCT00975143, a Phase 3 study, has completed, sponsored by Cipher Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 925 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
Interventions
- DRUG Isotretinoin
- DRUG CIP-Isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 925 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00975143
The ClinicalTrials.gov registry entry for NCT00975143 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 925 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cipher Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isotretinoin is the first listed.
NCT00975143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00975143 about?
NCT00975143 is a clinical study titled "Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne". The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
What is the current status of trial NCT00975143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 925 participants. The study started on 2009-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00975143?
The interventions under investigation include: Isotretinoin (DRUG), CIP-Isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00975143?
This trial is sponsored by Cipher Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.